Regeneron Pharmaceuticals Inc (REGN.O): 2026 CEO/CFO Call Series Takeaways: Core franchises support shares as focus turns to catalysts

Research evidence excerpt

Regeneron Pharmaceuticals Inc (REGN.O): 2026 CEO/CFO Call Series Takeaways: Core franchises support shares as focus turns to catalysts

Flash |

18 Jun 2026 14:34:04 ET │ 11 pages

Regeneron Pharmaceuticals Inc (REGN.O)

2026 CEO/CFO Call Series Takeaways: Core franchises support shares

as focus turns to catalysts

CITI’S TAKE Neutral

Our 2026 CEO/CFO call series wrapped up with Regeneron’s CFO Chris Price (17 Jun 26 16:00) US$607.93

Fenimore, with discussion focused on capital allocation, BD/M&A Target price US$700.00

discipline, EYLEA-HD, Dupixent durability/lifecycle management, and

Expected share price return 15.1% selected pipeline opportunities. Management’s message was consistent

with Regeneron’s historical strategy: Internal R&D remains the first call on Expected dividend yield 0.1%

capital, external innovation is used selectively to complement internal Expected total return 15.2%

capabilities, and shareholder returns remain flexible through buybacks Market Cap US$63,735M

and a modest dividend. On key products, management reiterated

confidence in EYLEA-HD momentum despite aggregate retina pressure,

while Dupixent commentary remained constructive on COPD/CSU

uptake, high persistence, and lifecycle optionality. Overall, the discussion Geoff Meacham, Ph.D.AC

reinforced Regeneron’s high-quality profile, supported by durable cash +1-404-443-4701

generation, deep science, and broad long-term optionality. Indeed, geoffrey.meacham@citi.com

Dupixent and Libtayo remain bright spots, but continued EYLEA franchise Nishant Gandhi, Ph.D.

pressure, the need for clearer pipeline conversion, and limited near-term +1-212-816-2513

catalysts to shift the narrative keep us on the sidelines. Maintain Neutral, nishant.gandhi@citi.com

TP $700. (Replay link.) Jarwei Fang